Risk of Reliance on a Stagnant Generic Drug Market
First written in FY2016. 19 of 24 entries say "Restated". Latest entry: 2026-10-14.
0 other companies' latest entry also says "Restated".
- FY2025RestatedAnnual report
「In the fiscal year ending May 2025, consolidated sales related to generic drugs accounted for approximately 80% of the Group's total consolidated sales.」
The text continues to describe a structure in which generic-related sales account for approximately 80% of consolidated sales, and explains market trends together with an 86.5% volume share and the new roadmap. - FY2025-H1WorsenedAnnual report
「Meanwhile, the Basic Policy on Economic and Fiscal Management and Reform 2024 states that the government will promote structural reform with a view to the ideal form of the generic drug industry, including industry consolidation, and establish a legal framework for stable supply. It is expected that steps will be taken to eliminate shortages of generic drugs and establish a supply structure capable of supporting continued measures to promote their use.」
Amid continued reliance on the generic drug market, supply shortages, industry consolidation, and the establishment of a stable supply structure are described as new challenges in the industry environment, in addition to conventional drug price revisions and other factors. - FY2024RestatedAnnual report
「In the fiscal year from April 2023 to March 2024, the volume share reached 82.7% (according to the Japan Generic Medicines Association), and the adoption of generic drugs continued to expand. In the fiscal year ending May 2024, consolidated sales related to generic drugs accounted for approximately 80% of the Group's total consolidated sales.」
While indicating the expansion of generic drugs' volume share, the text continues to describe a structure dependent on related sales accounting for approximately 80% of consolidated sales. - FY2024-Q3RestatedAnnual report
「In the pharmaceutical industry, the government has been promoting the use of generic drugs, and the Basic Policy on Economic and Fiscal Management and Reform 2021 sets out a policy of ensuring confidence in the quality and stable supply of generic drugs, as well as promoting their use. Meanwhile, in addition to biennial drug price revisions from fiscal 2021, annual revisions have been implemented, including revisions in interim years. The business environment for the pharmaceutical industry has become increasingly challenging, and we are required to make further efforts to improve management efficiency.」
While describing policies to promote the use of generic drugs, the text continues to indicate the challenging business environment resulting from annual drug price revisions and the need to improve management efficiency amid conditions surrounding the generic drug market. - FY2024-Q2RestatedAnnual report
「In the pharmaceutical industry, the government has been promoting the use of generic drugs, and the Basic Policy on Economic and Fiscal Management and Reform 2021 sets out a policy of ensuring confidence in the quality and stable supply of generic drugs, as well as promoting their use. Meanwhile, in addition to biennial drug price revisions from fiscal 2021, annual revisions have been implemented, including revisions in interim years. The business environment for the pharmaceutical industry has become increasingly challenging, and we are required to make further efforts to improve management efficiency.」
The text continues to describe the policy of promoting the use of generic drugs, the challenging business environment resulting from annual drug price revisions, and the need to improve management efficiency, as before. - FY2024-Q1RestatedAnnual report
「In the pharmaceutical industry, the government has been promoting the use of generic drugs, and the Basic Policy on Economic and Fiscal Management and Reform 2021 sets out a policy of ensuring confidence in the quality and stable supply of generic drugs, as well as promoting their use. Meanwhile, in addition to biennial drug price revisions from fiscal 2021, annual revisions have been implemented, including revisions in interim years. The business environment for the pharmaceutical industry has become increasingly challenging, and we are required to make further efforts to improve management efficiency.」
While describing policies to promote the use of generic drugs, the text continues to indicate the challenging business environment resulting from annual drug price revisions and the need to improve management efficiency in light of the reliance on the generic drug market. - FY2023RestatedAnnual report
「In the fiscal year from April 2022 to March 2023, the volume share reached 80.7% (according to the Japan Generic Medicines Association), and the adoption of generic drugs continued to expand. In the fiscal year ending May 2023, consolidated sales related to generic drugs accounted for approximately 80% of the Group's total consolidated sales.」
While showing that the volume share of generic drugs rose to 80.7%, the text continues to describe a structure in which generic-related sales account for approximately 80% of consolidated sales. - FY2023-Q3RestatedAnnual report
「Meanwhile, in addition to biennial drug price revisions from fiscal 2021, annual revisions have been implemented, including revisions in interim years. The business environment for the pharmaceutical industry has become increasingly challenging, and we are required to make further efforts to improve management efficiency.」
While noting measures to promote the use of generic drugs, the text continues to describe the challenging business environment resulting from annual drug price revisions and the need to improve management efficiency. - FY2022-Q3RestatedAnnual report
「While adoption of generic drugs has expanded, drug prices were revised in April 2022 and annual revisions thereafter were decided. The operating environment for the pharmaceutical industry is therefore expected to become challenging, requiring the company to make further efforts to improve management efficiency.」
The company continues to present both the expanded adoption of generic drugs and the challenging operating environment resulting from the drug-price revision in April 2022 and annual revisions thereafter. - FY2022-Q2RestatedAnnual report
「While adoption of generic drugs has expanded, drug prices were revised in April 2021 and annual revisions thereafter were decided. The operating environment for the pharmaceutical industry is therefore expected to become challenging, requiring the company to make further efforts to improve management efficiency.」
The company continues to present both the expanded adoption of generic drugs and the challenging operating environment resulting from annual drug-price revisions. - FY2022-Q1RestatedAnnual report
「While adoption of generic drugs has expanded, drug prices were revised in April 2021 and annual revisions thereafter were decided. The operating environment for the pharmaceutical industry is therefore expected to become challenging, requiring the company to make further efforts to improve management efficiency.」
The company continues to present both the expanded adoption of generic drugs and the challenging operating environment resulting from annual drug-price revisions. - FY2021-Q3RestatedAnnual report
「In the October-December 2020 quarter, the volume share reached 79.4%, according to the Japan Generic Medicines Association, and adoption of generic drugs continued to expand. However, a drug-price revision associated with the consumption-tax increase was implemented in October 2019, and the regular drug-price revision conducted once every 2 years was implemented in April 2020. In addition, drug prices were revised in April 2021, and annual drug-price revisions thereafter were decided. The operating environment for the pharmaceutical industry is therefore expected to become challenging.」
While indicating an increase in volume share and expanded adoption, the company continues to describe the challenging environment surrounding its dependence on the generic market, noting that drug prices were revised in April 2021 and that annual revisions have been decided for the future. - FY2021-Q2Volume share declined quarter on quarterAnnual report
「In the July-September 2020 quarter, the volume share reached 78.9%, according to the Japan Generic Medicines Association, and adoption of generic drugs continued to expand. However, a drug-price revision associated with the consumption-tax increase was implemented in October 2019, and the regular drug-price revision conducted once every 2 years was implemented in April 2020. It was also decided that a fiscal 2021 drug-price revision and annual revisions thereafter would be implemented. The operating environment for the pharmaceutical industry is therefore expected to become challenging.」
The volume share of generic drugs declined to 78.9% from 79.3% in the previous quarter. While describing expanded adoption driven by policies promoting generic-drug use, the company also notes the challenging operating environment resulting from annual drug-price revisions from fiscal 2021 onward. - FY2021-Q1RestatedAnnual report
「However, a drug-price revision associated with the consumption-tax increase was implemented in October 2019, and the regular drug-price revision conducted once every 2 years was implemented in April 2020. The Basic Policy on Economic and Fiscal Management and Reform 2020, approved by the Cabinet in July 2020, stated that the fiscal 2021 drug-price revision would be considered and decided after taking into account the impact of COVID-19. Nevertheless, a fiscal 2021 drug-price revision and annual drug-price revisions thereafter were scheduled, and the operating environment for the pharmaceutical industry was expected to become challenging.」
The company continues to describe the challenging operating environment resulting from the implementation of drug-price revisions and plans for annual revisions. It also added that the fiscal 2021 revision would be considered and decided after taking into account the impact of COVID-19. - FY2020-Q3RestatedAnnual report
「In the October-December 2019 quarter, the volume share reached 77.1%, according to the Japan Generic Medicines Association, and adoption of generic drugs continued to expand. In addition, the Basic Policy on Economic and Fiscal Management and Reform 2019, approved by the Cabinet in June 2019, explicitly stated that efforts would continue to achieve an 80% generic-drug utilization rate by September 2020, including stronger incentives, while ensuring stable supply and further quality assurance. However, a drug-price revision associated with the consumption-tax increase was implemented in October 2019, and the regular drug-price revision conducted once every 2 years was implemented in April 2020. It was also decided that drug prices would be revised annually from fiscal 2021. The operating environment for the pharmaceutical industry is therefore expected to remain challenging, requiring the company to make further efforts to improve management efficiency.」
While indicating policies promoting generic-drug use and an increase in volume share, the company continues to explain that the operating environment in its dependent market is challenging due to the drug-price revision associated with the consumption-tax increase, the regular drug-price revision, and annual revisions from fiscal 2021. - FY2020-Q2RestatedAnnual report
「In the July-September 2019 quarter, the volume share reached 76.9%, according to the Japan Generic Medicines Association, and adoption of generic drugs continued to expand. In addition, the Basic Policy on Economic and Fiscal Management and Reform 2019, approved by the Cabinet in June 2019, explicitly stated that efforts would continue to achieve an 80% generic-drug utilization rate by September 2020, including stronger incentives, while ensuring stable supply and further quality assurance. However, a drug-price revision associated with the consumption-tax increase was implemented in October 2019, and the regular drug-price revision conducted once every 2 years was scheduled for April 2020. It was also decided that drug prices would be revised annually from fiscal 2021. The operating environment for the pharmaceutical industry is therefore expected to remain challenging, requiring the company to make further efforts to improve management efficiency.」
While indicating policies promoting generic-drug use and an increase in volume share, the company continues to describe the challenging environment surrounding its dependent market due to the drug-price revision associated with the consumption-tax increase, the regular revision in April 2020, and annual revisions from fiscal 2021. - FY2020-Q1RestatedAnnual report
「The Basic Policy on Economic and Fiscal Management and Reform 2017, approved by the Cabinet in June 2017, explicitly stated that the government would aim for an 80% generic-drug utilization rate by September 2020 and consider further measures to achieve this as early as possible. The government's policies promoting generic-drug use were implemented, and the volume share reached 75.8% in the period from April to June 2019, according to the Japan Generic Medicines Association. The adoption of generic drugs has therefore expanded. At the same time, policies to contain drug expenditure through drug-price cuts and other measures have been announced. In December 2017, the Central Social Insurance Medical Council approved the outline of reforms to the drug-pricing system, including annual drug-price revisions from fiscal 2021 instead of once every 2 years and substantial price cuts for originator drugs for which generic drugs have become widely used. As a result, the operating environment for the pharmaceutical industry is expected to become challenging.」
While indicating policies promoting generic-drug use and an increase in volume share, the company continues to describe the outlook for a challenging operating environment due to drug-price cuts and drug-expenditure controls. - FY2019-Q3RestatedAnnual report
「At the same time, policies to contain drug expenditure through drug-price cuts and other measures have been announced. In December 2017, the Central Social Insurance Medical Council approved the outline of reforms to the drug-pricing system, including annual drug-price revisions from fiscal 2021 instead of once every 2 years and substantial price cuts for originator drugs for which generic drugs have become widely used. As a result, the operating environment for the pharmaceutical industry is expected to become challenging.」
While indicating policy support for promoting generic-drug use, the company continues from the previous quarter to describe the outlook for a challenging operating environment due to drug-expenditure controls and drug-pricing reforms. - FY2019-Q1WorsenedAnnual report
「Competition has intensified as a result of the proper use of pharmaceuticals and the sale of authorized generics (AGs), particularly for major products. In addition, the NHI drug price revision was implemented from April 2018, and drug prices fell by 7.48% on a drug-expenditure basis, making the operating environment for Japan's pharmaceutical industry challenging.」
Regarding the environment surrounding its dependence on generic-related sales, the company cites intensifying competition from AGs and a 7.48% decline in drug prices on a drug-expenditure basis. - FY2018WorsenedAnnual report
「Competition has intensified as a result of the proper use of pharmaceuticals and the sale of authorized generics (AGs), particularly for major products, and growth in the generic-drug market has begun to show signs of slowing.」
While maintaining a structure dependent on generic-related sales for approximately 80% of consolidated revenue, the company specifically describes intensifying competition and slowing market growth. - FY2017RestatedAnnual report
「In the fiscal year ended May 2017, consolidated sales related to generic drugs accounted for approximately 80% of the group's total consolidated sales.」
Generic-related sales account for approximately 80% of consolidated sales, and the company continues to disclose the risk of dependence on a stagnant market. - FY2016First statedAnnual report
「In the fiscal year ended May 2016, consolidated sales related to generic drugs accounted for approximately 80% of the group's total consolidated sales.」
The company states that a stagnation in generic-market growth due to policy changes or other factors could affect its business performance and other results.